Clinical Trial

A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to assess the efficacy of vonoprazan 20 mg once daily (QD) compared to placebo QD in the number of participants with a peak eosinophilic histologic response \<15 eosinophils per high-power field (eos/hpf) after 12 weeks of therapy.
Protocol Amendment History 4 changes
notable Trial status changed: Recruiting → Active, Not Recruiting 2026-06-30
notable Enrollment increased: 80 -> 95 participants 2026-06-30
minor Primary completion moved earlier: 2026-12 -> 2026-10 2026-06-30
minor Completion moved earlier: 2027-03 -> 2027-01 2026-06-30
Trial Details
NCT Number NCT06851559
Lead Sponsor Phathom Pharmaceuticals, Inc.
Conditions Eosinophilic Esophagitis
Enrollment 95 participants
Start Date 2025-10-30
Primary Completion 2026-10 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-29